AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Filippos Maniatis, Healthcare Analyst at GlobalData, remarks, "With Dupixent setting the gold standard for AD, Sanofi has raised the bar for competitors in this space. However, Sanofi’s CEO has ...

Rinvoq's total estimated spending came in about $40 million behind Skyrizi's total last year, according to iSpot.TV, while Dupixent's total ... off on traditional TV advertising for its obesity ...

“Having Dupixent as the gold standard for AD, Sanofi has set a high benchmark for competitors within the space. Nevertheless, Sanofi’s CEO has underscored the need for increased ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships in 2025. Click for this ARQT update.

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...